Дата:	--/--/-- --:--:--
Id события:	E5DDR3QP7
Тип действия:	ACQUISITION
Статус действия:	ANNOUNCED
Символ покупателя:
Целевой символ:	LAB
Обновлено:	--/--/-- --:--:--
Цена покупки за акцию:
Цена за акцию в валюте:
Ссылки на новости:	https://www.prnewswire.com/news-releases/illumina-to-acquire-somalogic-accelerating-its-proteomics-business-and-advancing-the-companys-multiomics-strategy-302488151.html

Action Notes

Illumina, Inc. (NASDAQ: ILMN) announced today it has entered into a definitive agreement with Standard BioTools (NASDAQ: LAB) under which Illumina will acquire SomaLogic, a leader in data-driven proteomics technology, and other specified assets for $350 million in cash payable at closing, subject to customary adjustments, plus up to $75 million in near-term performance-based milestones and performance-based royalties.Completion of the transaction is subject to customary closing conditions, including the receipt of required regulatory clearance. The parties intend to make the necessary filing under the Hart-Scott-Rodino Act in the United States in due course. Illumina expects to close the transaction in the first half of 2026. Until then, the companies will continue to operate as separate and independent entities.